The global Anti-Parkinson Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Covers:

This report presents an overview of global market for Anti-Parkinson Drugs market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Anti-Parkinson Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Anti-Parkinson Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-Parkinson Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Anti-Parkinson Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Anti-Parkinson Drugs revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Anti-Parkinson Drugs Market Report

Report Metric	Details
Report Name	Anti-Parkinson Drugs Market
CAGR	5%
Segment by Type	Dopaminergic Dopamine Agonists Enzyme Inhibitors Others
Segment by Application	Hospital Pharmacy Retail Pharmacy Online Stores
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AbbVie, Mylan Laboratories, Valeant Pharmaceuticals, Novartis, GlaxoSmithKline, Zambon Pharmaceuticals, Pfizer, Inc., Hoffmann-La Roche, Merck & Co., Orion Pharma, UCB, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Anti-Parkinson Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Parkinson Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Parkinson Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

Who are the main players in the Anti-Parkinson Drugs Market report?

Ans: The main players in the Anti-Parkinson Drugs Market are AbbVie, Mylan Laboratories, Valeant Pharmaceuticals, Novartis, GlaxoSmithKline, Zambon Pharmaceuticals, Pfizer, Inc., Hoffmann-La Roche, Merck & Co., Orion Pharma, UCB, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc.

What are the Application segmentation covered in the Anti-Parkinson Drugs Market report?

Ans: The Applications covered in the Anti-Parkinson Drugs Market report are Hospital Pharmacy, Retail Pharmacy, Online Stores

What are the Type segmentation covered in the Anti-Parkinson Drugs Market report?

Ans: The Types covered in the Anti-Parkinson Drugs Market report are Dopaminergic, Dopamine Agonists, Enzyme Inhibitors, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Anti-Parkinson Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Dopaminergic

1.2.3 Dopamine Agonists

1.2.4 Enzyme Inhibitors

1.2.5 Others

1.3 Market by Application

1.3.1 Global Anti-Parkinson Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Online Stores

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Anti-Parkinson Drugs Market Perspective (2019-2030)

2.2 Global Anti-Parkinson Drugs Growth Trends by Region

2.2.1 Anti-Parkinson Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Anti-Parkinson Drugs Historic Market Size by Region (2019-2024)

2.2.3 Anti-Parkinson Drugs Forecasted Market Size by Region (2025-2030)

2.3 Anti-Parkinson Drugs Market Dynamics

2.3.1 Anti-Parkinson Drugs Industry Trends

2.3.2 Anti-Parkinson Drugs Market Drivers

2.3.3 Anti-Parkinson Drugs Market Challenges

2.3.4 Anti-Parkinson Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Anti-Parkinson Drugs by Players

3.1.1 Global Anti-Parkinson Drugs Revenue by Players (2019-2024)

3.1.2 Global Anti-Parkinson Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Anti-Parkinson Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Anti-Parkinson Drugs, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global Anti-Parkinson Drugs Market Concentration Ratio

3.4.1 Global Anti-Parkinson Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Anti-Parkinson Drugs Revenue in 2023

3.5 Global Key Players of Anti-Parkinson Drugs Head office and Area Served

3.6 Global Key Players of Anti-Parkinson Drugs, Product and Application

3.7 Global Key Players of Anti-Parkinson Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Anti-Parkinson Drugs Breakdown Data by Type

4.1 Global Anti-Parkinson Drugs Historic Market Size by Type (2019-2024)

4.2 Global Anti-Parkinson Drugs Forecasted Market Size by Type (2025-2030)

5 Anti-Parkinson Drugs Breakdown Data by Application

5.1 Global Anti-Parkinson Drugs Historic Market Size by Application (2019-2024)

5.2 Global Anti-Parkinson Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Anti-Parkinson Drugs Market Size (2019-2030)

6.2 North America Anti-Parkinson Drugs Market Size by Type

6.2.1 North America Anti-Parkinson Drugs Market Size by Type (2019-2024)

6.2.2 North America Anti-Parkinson Drugs Market Size by Type (2025-2030)

6.2.3 North America Anti-Parkinson Drugs Market Share by Type (2019-2030)

6.3 North America Anti-Parkinson Drugs Market Size by Application

6.3.1 North America Anti-Parkinson Drugs Market Size by Application (2019-2024)

6.3.2 North America Anti-Parkinson Drugs Market Size by Application (2025-2030)

6.3.3 North America Anti-Parkinson Drugs Market Share by Application (2019-2030)

6.4 North America Anti-Parkinson Drugs Market Size by Country

6.4.1 North America Anti-Parkinson Drugs Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America Anti-Parkinson Drugs Market Size by Country (2019-2024)

6.4.3 North America Anti-Parkinson Drugs Market Size by Country (2025-2030)

6.4.4 U.S.

6.4.5 Canada

7 Europe

7.1 Europe Anti-Parkinson Drugs Market Size (2019-2030)

7.2 Europe Anti-Parkinson Drugs Market Size by Type

7.2.1 Europe Anti-Parkinson Drugs Market Size by Type (2019-2024)

7.2.2 Europe Anti-Parkinson Drugs Market Size by Type (2025-2030)

7.2.3 Europe Anti-Parkinson Drugs Market Share by Type (2019-2030)

7.3 Europe Anti-Parkinson Drugs Market Size by Application

7.3.1 Europe Anti-Parkinson Drugs Market Size by Application (2019-2024)

7.3.2 Europe Anti-Parkinson Drugs Market Size by Application (2025-2030)

7.3.3 Europe Anti-Parkinson Drugs Market Share by Application (2019-2030)

7.4 Europe Anti-Parkinson Drugs Market Size by Country

7.4.1 Europe Anti-Parkinson Drugs Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe Anti-Parkinson Drugs Market Size by Country (2019-2024)

7.4.3 Europe Anti-Parkinson Drugs Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Anti-Parkinson Drugs Market Size (2019-2030)

8.2 China Anti-Parkinson Drugs Market Size by Type

8.2.1 China Anti-Parkinson Drugs Market Size by Type (2019-2024)

8.2.2 China Anti-Parkinson Drugs Market Size by Type (2025-2030)

8.2.3 China Anti-Parkinson Drugs Market Share by Type (2019-2030)

8.3 China Anti-Parkinson Drugs Market Size by Application

8.3.1 China Anti-Parkinson Drugs Market Size by Application (2019-2024)

8.3.2 China Anti-Parkinson Drugs Market Size by Application (2025-2030)

8.3.3 China Anti-Parkinson Drugs Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Anti-Parkinson Drugs Market Size (2019-2030)

9.2 Asia Anti-Parkinson Drugs Market Size by Type

9.2.1 Asia Anti-Parkinson Drugs Market Size by Type (2019-2024)

9.2.2 Asia Anti-Parkinson Drugs Market Size by Type (2025-2030)

9.2.3 Asia Anti-Parkinson Drugs Market Share by Type (2019-2030)

9.3 Asia Anti-Parkinson Drugs Market Size by Application

9.3.1 Asia Anti-Parkinson Drugs Market Size by Application (2019-2024)

9.3.2 Asia Anti-Parkinson Drugs Market Size by Application (2025-2030)

9.3.3 Asia Anti-Parkinson Drugs Market Share by Application (2019-2030)

9.4 Asia Anti-Parkinson Drugs Market Size by Region

9.4.1 Asia Anti-Parkinson Drugs Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia Anti-Parkinson Drugs Market Size by Region (2019-2024)

9.4.3 Asia Anti-Parkinson Drugs Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Type

10.2.1 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Application

10.3.1 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Country

10.4.1 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 AbbVie

11.1.1 AbbVie Company Details

11.1.2 AbbVie Business Overview

11.1.3 AbbVie Anti-Parkinson Drugs Introduction

11.1.4 AbbVie Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.1.5 AbbVie Recent Developments

11.2 Mylan Laboratories

11.2.1 Mylan Laboratories Company Details

11.2.2 Mylan Laboratories Business Overview

11.2.3 Mylan Laboratories Anti-Parkinson Drugs Introduction

11.2.4 Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.2.5 Mylan Laboratories Recent Developments

11.3 Valeant Pharmaceuticals

11.3.1 Valeant Pharmaceuticals Company Details

11.3.2 Valeant Pharmaceuticals Business Overview

11.3.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Introduction

11.3.4 Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.3.5 Valeant Pharmaceuticals Recent Developments

11.4 Novartis

11.4.1 Novartis Company Details

11.4.2 Novartis Business Overview

11.4.3 Novartis Anti-Parkinson Drugs Introduction

11.4.4 Novartis Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.4.5 Novartis Recent Developments

11.5 GlaxoSmithKline

11.5.1 GlaxoSmithKline Company Details

11.5.2 GlaxoSmithKline Business Overview

11.5.3 GlaxoSmithKline Anti-Parkinson Drugs Introduction

11.5.4 GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.5.5 GlaxoSmithKline Recent Developments

11.6 Zambon Pharmaceuticals

11.6.1 Zambon Pharmaceuticals Company Details

11.6.2 Zambon Pharmaceuticals Business Overview

11.6.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Introduction

11.6.4 Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.6.5 Zambon Pharmaceuticals Recent Developments

11.7 Pfizer, Inc.

11.7.1 Pfizer, Inc. Company Details

11.7.2 Pfizer, Inc. Business Overview

11.7.3 Pfizer, Inc. Anti-Parkinson Drugs Introduction

11.7.4 Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.7.5 Pfizer, Inc. Recent Developments

11.8 Hoffmann-La Roche

11.8.1 Hoffmann-La Roche Company Details

11.8.2 Hoffmann-La Roche Business Overview

11.8.3 Hoffmann-La Roche Anti-Parkinson Drugs Introduction

11.8.4 Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.8.5 Hoffmann-La Roche Recent Developments

11.9 Merck & Co.

11.9.1 Merck & Co. Company Details

11.9.2 Merck & Co. Business Overview

11.9.3 Merck & Co. Anti-Parkinson Drugs Introduction

11.9.4 Merck & Co. Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.9.5 Merck & Co. Recent Developments

11.10 Orion Pharma

11.10.1 Orion Pharma Company Details

11.10.2 Orion Pharma Business Overview

11.10.3 Orion Pharma Anti-Parkinson Drugs Introduction

11.10.4 Orion Pharma Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.10.5 Orion Pharma Recent Developments

11.11 UCB

11.11.1 UCB Company Details

11.11.2 UCB Business Overview

11.11.3 UCB Anti-Parkinson Drugs Introduction

11.11.4 UCB Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.11.5 UCB Recent Developments

11.12 Teva Pharmaceutical Industries Ltd.

11.12.1 Teva Pharmaceutical Industries Ltd. Company Details

11.12.2 Teva Pharmaceutical Industries Ltd. Business Overview

11.12.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Introduction

11.12.4 Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.12.5 Teva Pharmaceutical Industries Ltd. Recent Developments

11.13 Vertical Pharmaceuticals, LLC

11.13.1 Vertical Pharmaceuticals, LLC Company Details

11.13.2 Vertical Pharmaceuticals, LLC Business Overview

11.13.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Introduction

11.13.4 Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.13.5 Vertical Pharmaceuticals, LLC Recent Developments

11.14 ACADIA Pharmaceuticals Inc.

11.14.1 ACADIA Pharmaceuticals Inc. Company Details

11.14.2 ACADIA Pharmaceuticals Inc. Business Overview

11.14.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Introduction

11.14.4 ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024)

11.14.5 ACADIA Pharmaceuticals Inc. Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

AbbVie

Mylan Laboratories

Valeant Pharmaceuticals

Novartis

GlaxoSmithKline PLC

Zambon Pharmaceuticals

Teva Pharmaceutical Industries Ltd

Vertical Pharmaceuticals LLC

ACADIA Pharmaceuticals Inc.

List of Tables

Table 1. Global Anti-Parkinson Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of Dopaminergic

Table 3. Key Players of Dopamine Agonists

Table 4. Key Players of Enzyme Inhibitors

Table 5. Key Players of Others

Table 6. Global Anti-Parkinson Drugs Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 7. Global Anti-Parkinson Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Anti-Parkinson Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 9. Global Anti-Parkinson Drugs Market Share by Region (2019-2024)

Table 10. Global Anti-Parkinson Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 11. Global Anti-Parkinson Drugs Market Share by Region (2025-2030)

Table 12. Anti-Parkinson Drugs Market Trends

Table 13. Anti-Parkinson Drugs Market Drivers

Table 14. Anti-Parkinson Drugs Market Challenges

Table 15. Anti-Parkinson Drugs Market Restraints

Table 16. Global Anti-Parkinson Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 17. Global Anti-Parkinson Drugs Revenue Share by Players (2019-2024)

Table 18. Global Top Anti-Parkinson Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson Drugs as of 2023)

Table 19. Global Anti-Parkinson Drugs Industry Ranking 2022 VS 2023 VS 2024

Table 20. Global 5 Largest Players Market Share by Anti-Parkinson Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 21. Global Key Players of Anti-Parkinson Drugs, Headquarters and Area Served

Table 22. Global Key Players of Anti-Parkinson Drugs, Product and Application

Table 23. Global Key Players of Anti-Parkinson Drugs, Product and Application

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Anti-Parkinson Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 26. Global Anti-Parkinson Drugs Revenue Market Share by Type (2019-2024)

Table 27. Global Anti-Parkinson Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 28. Global Anti-Parkinson Drugs Revenue Market Share by Type (2025-2030)

Table 29. Global Anti-Parkinson Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 30. Global Anti-Parkinson Drugs Revenue Share by Application (2019-2024)

Table 31. Global Anti-Parkinson Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 32. Global Anti-Parkinson Drugs Revenue Share by Application (2025-2030)

Table 33. North America Anti-Parkinson Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 34. North America Anti-Parkinson Drugs Market Size by Type (2025-2030) & (US$ Million)

Table 35. North America Anti-Parkinson Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 36. North America Anti-Parkinson Drugs Market Size by Application (2025-2030) & (US$ Million)

Table 37. North America Anti-Parkinson Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. North America Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 39. North America Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 40. Europe Anti-Parkinson Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 41. Europe Anti-Parkinson Drugs Market Size by Type (2025-2030) & (US$ Million)

Table 42. Europe Anti-Parkinson Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 43. Europe Anti-Parkinson Drugs Market Size by Application (2025-2030) & (US$ Million)

Table 44. Europe Anti-Parkinson Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Europe Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 46. Europe Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 47. China Anti-Parkinson Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 48. China Anti-Parkinson Drugs Market Size by Type (2025-2030) & (US$ Million)

Table 49. China Anti-Parkinson Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 50. China Anti-Parkinson Drugs Market Size by Application (2025-2030) & (US$ Million)

Table 51. Asia Anti-Parkinson Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 52. Asia Anti-Parkinson Drugs Market Size by Type (2025-2030) & (US$ Million)

Table 53. Asia Anti-Parkinson Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 54. Asia Anti-Parkinson Drugs Market Size by Application (2025-2030) & (US$ Million)

Table 55. Asia Anti-Parkinson Drugs Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 56. Asia Anti-Parkinson Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 57. Asia Anti-Parkinson Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 58. Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Type (2025-2030) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 61. Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Application (2025-2030) & (US$ Million)

Table 62. Middle East, Africa, and Latin America Anti-Parkinson Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 63. Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 64. Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 65. AbbVie Company Details

Table 66. AbbVie Business Overview

Table 67. AbbVie Anti-Parkinson Drugs Product

Table 68. AbbVie Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 69. AbbVie Recent Developments

Table 70. Mylan Laboratories Company Details

Table 71. Mylan Laboratories Business Overview

Table 72. Mylan Laboratories Anti-Parkinson Drugs Product

Table 73. Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 74. Mylan Laboratories Recent Developments

Table 75. Valeant Pharmaceuticals Company Details

Table 76. Valeant Pharmaceuticals Business Overview

Table 77. Valeant Pharmaceuticals Anti-Parkinson Drugs Product

Table 78. Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 79. Valeant Pharmaceuticals Recent Developments

Table 80. Novartis Company Details

Table 81. Novartis Business Overview

Table 82. Novartis Anti-Parkinson Drugs Product

Table 83. Novartis Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 84. Novartis Recent Developments

Table 85. GlaxoSmithKline Company Details

Table 86. GlaxoSmithKline Business Overview

Table 87. GlaxoSmithKline Anti-Parkinson Drugs Product

Table 88. GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 89. GlaxoSmithKline Recent Developments

Table 90. Zambon Pharmaceuticals Company Details

Table 91. Zambon Pharmaceuticals Business Overview

Table 92. Zambon Pharmaceuticals Anti-Parkinson Drugs Product

Table 93. Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 94. Zambon Pharmaceuticals Recent Developments

Table 95. Pfizer, Inc. Company Details

Table 96. Pfizer, Inc. Business Overview

Table 97. Pfizer, Inc. Anti-Parkinson Drugs Product

Table 98. Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 99. Pfizer, Inc. Recent Developments

Table 100. Hoffmann-La Roche Company Details

Table 101. Hoffmann-La Roche Business Overview

Table 102. Hoffmann-La Roche Anti-Parkinson Drugs Product

Table 103. Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 104. Hoffmann-La Roche Recent Developments

Table 105. Merck & Co. Company Details

Table 106. Merck & Co. Business Overview

Table 107. Merck & Co. Anti-Parkinson Drugs Product

Table 108. Merck & Co. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 109. Merck & Co. Recent Developments

Table 110. Orion Pharma Company Details

Table 111. Orion Pharma Business Overview

Table 112. Orion Pharma Anti-Parkinson Drugs Product

Table 113. Orion Pharma Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 114. Orion Pharma Recent Developments

Table 115. UCB Company Details

Table 116. UCB Business Overview

Table 117. UCB Anti-Parkinson Drugs Product

Table 118. UCB Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 119. UCB Recent Developments

Table 120. Teva Pharmaceutical Industries Ltd. Company Details

Table 121. Teva Pharmaceutical Industries Ltd. Business Overview

Table 122. Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Product

Table 123. Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 124. Teva Pharmaceutical Industries Ltd. Recent Developments

Table 125. Vertical Pharmaceuticals, LLC Company Details

Table 126. Vertical Pharmaceuticals, LLC Business Overview

Table 127. Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Product

Table 128. Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 129. Vertical Pharmaceuticals, LLC Recent Developments

Table 130. ACADIA Pharmaceuticals Inc. Company Details

Table 131. ACADIA Pharmaceuticals Inc. Business Overview

Table 132. ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Product

Table 133. ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)

Table 134. ACADIA Pharmaceuticals Inc. Recent Developments

Table 135. Research Programs/Design for This Report

Table 136. Key Data Information from Secondary Sources

Table 137. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Anti-Parkinson Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Anti-Parkinson Drugs Market Share by Type: 2023 VS 2030

Figure 3. Dopaminergic Features

Figure 4. Dopamine Agonists Features

Figure 5. Enzyme Inhibitors Features

Figure 6. Others Features

Figure 7. Global Anti-Parkinson Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 8. Global Anti-Parkinson Drugs Market Share by Application: 2023 VS 2030

Figure 9. Hospital Pharmacy Case Studies

Figure 10. Retail Pharmacy Case Studies

Figure 11. Online Stores Case Studies

Figure 12. Anti-Parkinson Drugs Report Years Considered

Figure 13. Global Anti-Parkinson Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global Anti-Parkinson Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Anti-Parkinson Drugs Market Share by Region: 2023 VS 2030

Figure 16. Global Anti-Parkinson Drugs Market Share by Players in 2023

Figure 17. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson Drugs as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by Anti-Parkinson Drugs Revenue in 2023

Figure 19. North America Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America Anti-Parkinson Drugs Market Share by Type (2019-2030)

Figure 21. North America Anti-Parkinson Drugs Market Share by Application (2019-2030)

Figure 22. North America Anti-Parkinson Drugs Market Share by Country (2019-2030)

Figure 23. United States Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Canada Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Anti-Parkinson Drugs Market Size YoY (2019-2030) & (US$ Million)

Figure 26. Europe Anti-Parkinson Drugs Market Share by Type (2019-2030)

Figure 27. Europe Anti-Parkinson Drugs Market Share by Application (2019-2030)

Figure 28. Europe Anti-Parkinson Drugs Market Share by Country (2019-2030)

Figure 29. Germany Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. France Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. U.K. Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Italy Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Russia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Nordic Countries Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. China Anti-Parkinson Drugs Market Size YoY (2019-2030) & (US$ Million)

Figure 36. China Anti-Parkinson Drugs Market Share by Type (2019-2030)

Figure 37. China Anti-Parkinson Drugs Market Share by Application (2019-2030)

Figure 38. Asia Anti-Parkinson Drugs Market Size YoY (2019-2030) & (US$ Million)

Figure 39. Asia Anti-Parkinson Drugs Market Share by Type (2019-2030)

Figure 40. Asia Anti-Parkinson Drugs Market Share by Application (2019-2030)

Figure 41. Asia Anti-Parkinson Drugs Market Share by Region (2019-2030)

Figure 42. Japan Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. South Korea Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. China Taiwan Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Southeast Asia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. India Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Australia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Size YoY (2019-2030) & (US$ Million)

Figure 49. Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Share by Type (2019-2030)

Figure 50. Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Share by Application (2019-2030)

Figure 51. Middle East, Africa, and Latin America Anti-Parkinson Drugs Market Share by Country (2019-2030)

Figure 52. Brazil Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 53. Mexico Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 54. Turkey Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 55. Saudi Arabia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. Israel Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 57. GCC Countries Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 58. AbbVie Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 59. Mylan Laboratories Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 60. Valeant Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 61. Novartis Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 62. GlaxoSmithKline Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 63. Zambon Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 64. Pfizer, Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 65. Hoffmann-La Roche Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 66. Merck & Co. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 67. Orion Pharma Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 68. UCB Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 69. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 70. Vertical Pharmaceuticals, LLC Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 71. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)

Figure 72. Bottom-up and Top-down Approaches for This Report

Figure 73. Data Triangulation

Figure 74. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Anti Parkinson s Disease Drugs Market Research Report 2024

Global Targeted Drugs for Parkinson s Disease Market Research Report 2024

Global Parkinson s Disease Treatment Market Insights Forecast to 2030

Global Drugs for Central Nervous System Diseases Market Insights Forecast to 2030

Global Parkinson Treatment Drug Market Research Report 2025

Global Leishmaniasis Treatment Market Insights Forecast to 2030

Global Diabetic Neurological Disorder Therapeutic Drug Market Insights Forecast to 2030

Global Parkinsons Disease Drug Market Insights Forecast to 2030

Global Rheumatic Disorders Drug Market Insights Forecast to 2030

Global Alzheimers and Parkinsons Diseases Market Insights Forecast to 2030

Global Parkinson s Disease PD Drugs Market Research Report 2024

Global Gaucher Disease GD Drugs Market Insights Forecast to 2030

Global Antidepressants Drugs Market Insights Forecast to 2030

Global ADHD Medications Market Insights Forecast to 2030

Global Neurodegenerative Disease Market Insights Forecast to 2030

Global Atherosclerosis Drugs Market Insights Forecast to 2030

Global Alzheimer s Disease Therapeutics and Diagnostics Market Insights Forecast to 2030

Global Cold Treatment Drug Market Insights Forecast to 2030

Global Parkinson s Disease Therapeutics Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions